Finanzen von Immuneering Corp (IMRX)IMRXImmuneering Corp

Evaluating the bottom line, Immuneering Corporation maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.15%, provide a clear picture of how effectively IMRX converts its operational activities into shareholder value.

In the context of the broader market, IMRX competes directly with industry leaders such as VNDA and PRQR. With a market capitalization of $327.37M, it holds a leading position in the sector. When comparing efficiency, IMRX's gross margin of N/A stands against VNDA's 89.02% and PRQR's 100.00%. Such benchmarking helps identify whether Immuneering Corporation is trading at a premium or discount relative to its financial performance.

Immuneering has reported consistent losses, with a Q2 2026 EPS of -0.27 and a forward P/E ratio of 0, indicating no earnings expected in the near term. Despite this, the company maintains a solid cash reserve of $182.7 million, providing a runway into 2029.